Is There a Generic for Zolymbus?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Zolymbus (bimatoprost). The Orange Book shows its last listed patent expires June 8, 2036 and its last listed exclusivity ends September 9, 2028.

Run it in Rivvi

Map Zolymbus and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Zolymbus products in the Orange Book

Zolymbus products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
gel, ophthalmic	0.01%	Marketed (Rx)	None	0	None

NDA 217307, held by THEA PHARMA INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Zolymbus patents

Patents listed for Zolymbus
Patent	Expires	Covers	Use code	NDA
10314780	June 8, 2036	Drug product	U-1295	217307

Zolymbus exclusivity

Exclusivity listed for Zolymbus
Code	Meaning	Expires	NDA
NDF	See the Orange Book exclusivity code list	September 9, 2028	217307

Zolymbus NDC codes

82584-010

Questions

Is there a generic for Zolymbus?

No. The Orange Book lists no active FDA-approved generic (ANDA) for Zolymbus (bimatoprost). The Orange Book shows its last listed patent expires June 8, 2036 and its last listed exclusivity ends September 9, 2028.

What is the generic name for Zolymbus?

The active ingredient in Zolymbus is bimatoprost, per the FDA Orange Book.

When does the Zolymbus patent expire?

The last patent listed for Zolymbus in the Orange Book expires June 8, 2036. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.